More Than 20 Patheon Scientists to Present at AAPS Annual Meeting

Patheon, the pharmaceutical services business owned by DPx Holdings B.V., and Banner Life Sciences will have more than 20 scientific posters presented at the AAPS Annual Meeting and Exposition from Sunday, Nov. 2, to Thursday, Nov. 6, in San Diego, Calif.

In addition to the more than 20 Patheon and Banner Life Sciences experts presenting posters, Anil Kane, Ph.D., MBA, Executive Director, Global Formulation Sciences, PDS at Patheon, and Bill Weiser, Ph.D., Global Head, PDS Analytical Sciences at Patheon, will give a corporate presentation focusing on “Solving Challenges from Discovery to Commercial Manufacturing of Drug Substance and Drug Products” on Tuesday, Nov. 4, 1 p.m. to 1:15 p.m. in the Corporate Presentation Theatre.

A complete listing of all posters Patheon and Banner Life Sciences will be presenting at AAPS follows.

Monday, Nov. 3, 1:30 p.m. to 5 p.m. poster sessions:

• Development of a Dissolution Test Method for Ibuprofen Soft Gelatin Capsules with a Lipid Based Formulation by Ad Bernaerts, Patheon
• Development and Qualification of a USP Apparatus 4 Tier II Method Using Formaldehyde Cross-Linked Soft Gelatin Capsules by Mae Cruz, Banner Life Sciences
• Development of a Two Step Pre-Treatment Tier 2 Apparatus 2 Dissolution Method for a Cross-linked Soft Gelatin Capsule Containing Hydrophilic PEG Fill by Mae Cruz, Banner Life Sciences
• Strategies for Improving the Extraction of Tertiary Amines Formulated with Ionic Excipients by Maureen McLaughlin, Patheon

Tuesday, Nov. 4, 9:30 a.m. to 12:30 p.m. poster sessions:

• An Easy Technique of Top Spray Granulation to Formulate a Compound with High Drug Load and Water Content by Amol Kheur, Patheon
• Correlation between Lyophilisation Cycle Parameters and Cake Morphology in a Biosimilar Product by Christian Abbati, Patheon
• Application of Enteric/Colonic Polymer Coating on Non-banded Size M Mouse Capsules Containing Immediate and Delayed/Sustained Release Formulations Using Model Compound Ibuprofen by Ian McIntosh, Patheon
• Softgel Capsules Imbedded with Micro Covert Marker for Anticounterfeiting Applications by Qi Fang, Banner Life Sciences

Tuesday, Nov. 4, 1:30 p.m. to 5 p.m. posters session:

• Assessing Disintegration of Softgel Formulations in the Gastric Compartment: Correlation Between Innovative In Vitro Test Through Dynamic Gastric Modelling and In Vivo Evaluation by Helena Teles, Patheon
• Effect of Aldehyde Level and Drug Particle Size on Dissolution Performance of Soft Gelatin Capsules by Mervin Williams, Jr., Banner Life Sciences
• Solubilization of Progesterone Enhanced Bioavailability in Male Beagle Dogs by Peijin Zhang, Banner Life Sciences

Wednesday, Nov. 5, 9:30 a.m. to 12:30 p.m. posters session:

• Formulation of Control Release Orally Disintegrating Tablets of Water Soluble Compounds by Arasu Kondappan, Patheon
• Liquid Filled Gelatin Hard Shell Capsule Physical Stability Study by Haibo Wang, Patheon
• Assay and Identification of Sylibin (Sylibin A and B) in Softgels® by Liquid Chromatography by Maria Isabel Morales, Banner Life Sciences
• Roller Compaction Process Design of Experiments: Small Scale Modeling of a Fixed Dose Combination Product to Facilitate Scale Up and Commercialization by Kimberley Pineau, Patheon
• Design of a Controlled Release SEDDS for a Poorly Soluble Drug in a Soft Gelatin Based Dosage Form by Saujanya Gosangari, Banner Life Sciences
• Small Scale Process Design to Facilitate Commercialization of a Wet Granulation Process Using Continuous Manufacturing by Stephen Closs, Patheon
• QbD Approach to the Development of Extended Release Matrix by Yunhua Hu, Banner Life Sciences

Thursday, Nov. 6, 8:30 a.m. to 11:30 a.m. posters session:

• Impact of Different Antioxidants in the Chemical Stability of a Complex Mixture Containing Vitamins, Minerals and Docosahexaenoic Acid (DHA) Suitable for Soft Gelatin Capsules by Adrian Callejas, Banner Life Sciences
• Impact of Mixing Shaft on Oxidation of Formulated Solution of L-Lactic Acid Salt for a Sterile Freeze-Dried Solid by Guendalina Rapone, Patheon
• Utilization of SoluPath to Provide Data-Driven Choices in Preclinical Formulation Development by Paul Sabo, Patheon
• An Alternate Approach for the Determination of Method Accuracy during the Validation of Karl Fischer Titration Methods by Stanley Wu, Patheon

DPx Holdings Media Relations

Tel: +1 (919) 210-0986

Email: media@patheon.com

About DPx Holdings B.V.

DPx Holdings B.V. is the privately held parent company of the Patheon, DPx Fine Chemicals and Banner Life Sciences businesses. The company is a leading provider of CDMO services, pharmaceutical products and products for other industries. DPx Holdings B.V. was founded in 2014 as a result of the merger of Patheon and DSM Pharmaceutical Products and is owned 51% by JLL Partners and 49% by Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. DPx Holdings B.V. offers customers unsurpassed quality, end-to-end services and value through its three business units. For more information, visit www.patheon.com/DPx.

About Patheon®

Patheon® is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms, including small molecule API and biologic drug substances. Patheon, a business unit of DPx Holdings B.V., encompasses the combined commercial manufacturing capabilities and pharmaceutical product development services, as well as offers a full array of biologic services and pharmaceutical active pharmaceutical ingredients (API) development. Patheon is #1 in product development services, #2 in commercial scale product manufacturing and is #1 in quality. For more information, visit http://www.patheon.com.

About Banner Life Sciences™

Established in 2013, Banner Life Sciences™ was formed as a result of the acquisition of Banner Pharmacaps by Patheon®. Banner Life Sciences is now a business unit of DPx Holdings B.V. and is dedicated to the research and development, in-licensing, out-licensing and commercialization of innovative formulation technologies, as well as the marketing of prescription, over-the-counter and nutritional proprietary products. For more information, visit http://www.bannerls.com.